| Biological insights from 108 schizophrenia-associated genetic loci C Pantelis, GN Papadimitriou, S Papiol, E Parkhomenko, MT Pato, ... Nature 511 (7510), 421-427, 2014 | 7732 | 2014 |
| Schizophrenia risk from complex variation of complement component 4 A Sekar, AR Bialas, H De Rivera, A Davis, TR Hammond, N Kamitaki, ... Nature 530 (7589), 177-183, 2016 | 2521 | 2016 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2296* | 2021 |
| Mapping genomic loci implicates genes and synaptic biology in schizophrenia V Trubetskoy, AF Pardiñas, T Qi, G Panagiotaropoulou, S Awasthi, ... Nature 604 (7906), 502-508, 2022 | 1804 | 2022 |
| Modeling linkage disequilibrium increases accuracy of polygenic risk scores BJ Vilhjálmsson, J Yang, HK Finucane, A Gusev, S Lindström, S Ripke, ... The american journal of human genetics 97 (4), 576-592, 2015 | 1466 | 2015 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 845 | 2021 |
| Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes DM Ruderfer, S Ripke, A McQuillin, J Boocock, EA Stahl, JMW Pavlides, ... Cell 173 (7), 1705-1715. e16, 2018 | 704 | 2018 |
| Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases A Gusev, SH Lee, G Trynka, H Finucane, BJ Vilhjálmsson, H Xu, C Zang, ... The American Journal of Human Genetics 95 (5), 535-552, 2014 | 688 | 2014 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 490* | 2022 |
| Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study D Hough, S Gopal, U Vijapurkar, P Lim, M Morozova, M Eerdekens Schizophrenia research 116 (2-3), 107-117, 2010 | 320 | 2010 |
| A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia GJ Pandina, JP Lindenmayer, J Lull, P Lim, S Gopal, V Herben, ... Journal of Clinical Psychopharmacology 30 (3), 235-244, 2010 | 273 | 2010 |
| Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial J Berwaerts, Y Liu, S Gopal, I Nuamah, H Xu, A Savitz, D Coppola, ... JAMA psychiatry 72 (8), 830-839, 2015 | 247 | 2015 |
| Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept B Franke, JL Stein, S Ripke, V Anttila, DP Hibar, KJE Van Hulzen, ... Nature neuroscience 19 (3), 420-431, 2016 | 244 | 2016 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 207 | 2021 |
| Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study S Gopal, DW Hough, H Xu, JM Lull, C Gassmann-Mayer, BM Remmerie, ... International clinical psychopharmacology 25 (5), 247-256, 2010 | 202 | 2010 |
| Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study AJ Savitz, H Xu, S Gopal, I Nuamah, P Ravenstijn, A Janik, A Schotte, ... International Journal of Neuropsychopharmacology 19 (7), pyw018, 2016 | 201 | 2016 |
| A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia G Pandina, R Lane, S Gopal, C Gassmann-Mayer, D Hough, B Remmerie, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 (1), 218-226, 2011 | 196 | 2011 |
| Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic … JJ McNamee, MA Gillies, NA Barrett, GD Perkins, W Tunnicliffe, D Young, ... Jama 326 (11), 1013-1023, 2021 | 185 | 2021 |
| A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia HA Nasrallah, S Gopal, C Gassmann-Mayer, JA Quiroz, P Lim, ... Neuropsychopharmacology 35 (10), 2072-2082, 2010 | 184 | 2010 |
| A comparison of ten polygenic score methods for psychiatric disorders applied across multiple cohorts G Ni, J Zeng, JA Revez, Y Wang, Z Zheng, T Ge, R Restuadi, J Kiewa, ... Biological psychiatry 90 (9), 611-620, 2021 | 176 | 2021 |
David Hough, MDChief Medical Officer at Freedom BiosciencesVahvistettu sähköpostiosoite verkkotunnuksessa freedombio.co